Managing Director, Woodside Way Ventures, Former Organizations: Five Prime Therapeutics, Medimmune, Amgen, Genzyme, Mednav, Inc.
Dr Sikorski is an independent drug developer focusing on advancing next-generation therapeutics through his company Woodside Way Ventures. Previously, as the Chief Medical Officer of FivePrime Therapeutics, he built a development organization, led clinical programs that advanced oncology drugs, and led the steering committee that managed a $350 million partnership agreement with BMS. As a Senior Director of Global Oncology Research and Development at Medimmune, he managed a clinical portfolio of 6 protein-based therapeutics in Phase l and ll clinical trials. They developed the initial PDL1 x CTLA4 combination regimen that advanced to a Phase III in lung cancer. As a Director of Global Oncology Research and Development at Amgen, he was instrumental in advancing a successful pivotal Phase III trial for Vectibix that gained European Marketing Authorization based on the first gene mutation companion diagnostic in colorectal cancer. Bob was also a medical affairs advisor to Genzyme and a CTO at Mednav, Inc. He is board-certified in both oncology and internal medicine. He has served as an editor for Science magazine and the Journal of the American Medical Association.